MV BioTherapeutics

MV BioTherapeutics (MV Bio), a Swiss Microbiota biotherapeutics & Vaccines company, has discovered the reciprocal shaping of the intestinal immune system and microbiota by adenosine triphosphate (ATP) released by bacteria. MV Bio’s technology is unique in conditioning the individual adaptive immune system in the gut and generated two lead products. MV002 in cancer immunotherapy as converter of patients refractory to immune checkpoint blockade (ICB) to responders. In combination with different ICB, MV002 more than doubles the percentage of tumor bearing animals responding to ICB. MV003, with indication in different pathophysiological conditions as corrector of dysbiosis.